CD44 and cancer: Expression of the majority (77.11%) of the homeobox genes analysed was altered in CSC compared to MaSC (CD44+/CD24-/low in HMEC) across different cancer subtypes (≥2-fold change, with genes considered differentially expressed only if either up-regulated or down-regulated in at least 2 cell lines of the same molecular subtype).